We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Johnson & Johnson's Cordis Corp. unit, which makes coronary stents, expects to resolve an outstanding warning letter from the Food and Drug Administration later this year, group chairman Rick Anderson said Wednesday during the health-care giant's medical devices and diagnostics business review with analysts.
One of the vexing challenges facing young biotechnology, pharmaceutical and medical technology companies involves finding money to turn their ideas into reality.
In written testimony to a two-day joint panel meeting of the U.S. Food and Drug Administration (FDA), the American Dental Association (ADA) reaffirmed its position that dental amalgam is a safe and effective cavity-filling material.
Patients could soon provide a pin-prick blood sample in the comfort of their home, and minutes later, be discussing the test results with their doctor thanks to a new Australian technology.
Penlon has issued an urgent product information notice on its Sigma Delta Sevoflurane vaporizer, distributed by Baxter in the UK, Penlon said recently.
Becton Dickinson (BD) has collaborated with TriPath since 2001 in developing cancer biomarkers and has reached a definitive agreement to acquire the remaining 93.5 percent of TriPath shares for $350 million, according to a research report by analyst Jeffrey Frelick of Lazard Capital Markets.
An in vitro diagnostic manufacturer failed to investigate root causes of nonconformances, including fungus and mold growth, the FDA said in a recent warning letter.
William Peters co-founded Sunshine Heart, which announced that it would use the money to complete an Australasian clinical trial of the C-Pulse heart device in human heart failure cases.
A federal judge awarded $10.3 million in damages and attorney fees Tuesday to an Oklahoma City cardiologist who alleged that patents for an angioplasty catheter he invented were infringed upon.
Boston Scientific Corp. says a new internal analysis of its clinical data confirms an increased risk of blood clots with its drug-coated cardiac stent.